Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: Prognostic factors for time to recurrence and progression

BJU International

Volumn 93, Issue 7, 2004, Pages 980-984

  Andius, P ^a   Holmang S ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BCG; Bladder neoplasm; Disease progression; Maintenance therapy

Indexed keywords

BCG VACCINE; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; BCG VACCINATION; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; CONFERENCE PAPER; CONTROLLED STUDY; CYSTOSCOPY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ARTICLE; BLADDER TUMOR; CYSTECTOMY; EPIDEMIOLOGY; INTRAVESICAL DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; TIME; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 2542540515     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04764.x     Document Type: Conference Paper

References (16)

1. Mostofi FK, Sorbin LH, Torloni H. Histologic typing of urinary bladder tumors. In International Histological Classification of Tumors, No. 10. Geneva: WHO, 1973
2. Holmäng S, Hedelin H, Anderström C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell carcinoma of the bladder followed for at least 20 years. J Urol 1995; 153: 1823-6
3. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology group study. J Urol 2000; 163: 1124-9
4. Sylvester RJ, van der Meijden A, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized trials. J Urol 2002; 168: 1964-70
5. Takashi M, Wakai K, Hattori T et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol 2002; 33: 41-7
6. Krogh J, Kvist, Rye B. Transitional cell carcinoma of the upper urinary tract: prognostic variables and postoperative recurrences. Br J Urol 1991; 67: 32-6
7. Mukamel E, Simon D, Edelman A, Konichezky M, Hadar H, Servadio C. Metachronous bladder tumors in patients with upper urinary tract transitional cell carcinoma. J Surg Oncol 1994; 57: 187-90
8. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2). the importance of recurrence pattern following initial resection. J Urol 1986; 135: 920-2
9. Badalament RA, Herr HW, Wong GY et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 1987; 5: 441-9
10. Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; 164: 685-9
11. Lockyer CR, Sedgwick JE, Gillatt DA. Beware the BCG failures: a review of one institution's results. Eur Urol 2002; 42: 542-6
12. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; 169: 1706-8
13. Saint F, Irani J, Patard JJ et al. Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 2001; 57: 883-8
14. Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J Urol 1982; 128: 1104-8
15. Lüftenegger W, Ackermann DK, Futterlieb A et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996; 155: 483-7
16. Zlotta AR, van Vooren JP, Huygen K et al. What is the optimal regimen for BCG intravesical therapy? Eur Urol 2000; 37: 470-7